抗线粒体靶向药物CPI-613治疗晚期恶性肿瘤患者急性肾损伤发生率的单中心回顾性研究
该单中心回顾性研究纳入33例既往参加3项开放标签II期研究的复发/难治性恶性肿瘤患者,接受单药CPI-613化疗。结果显示9例(27%)发生AKI,其中5例(15%)除CPI-613外未发现其他可能病因,年龄每增加5岁与AKI风险升高相关(调整HR 2.01,95%CI 1.06-3.79,P=0.03)。
要点
- CPI-613治疗期间AKI发生率为27%,其中15%无其他明确病因。
- 年龄每增加5岁,AKI风险调整HR为2.01(95%CI 1.06-3.79,P=0.03)。
- 多数AKI患者肾功能完全或部分恢复,但需密切监测。
核心结论
- AKI是线粒体靶向化疗CPI-613治疗期间可能出现的并发症。
研究设计与样本
- 单中心回顾性研究,纳入33例复发/难治性恶性肿瘤患者,来自3项开放标签II期研究,接受单药CPI-613化疗。
- AKI按KDIGO血清肌酐标准定义,中位随访120.0(74.0-301.0)天。
主要发现
- 9例(27%)患者发生AKI,其中5例(15%)除CPI-613外未发现其他潜在病因。
- 5例中AKI分期:1期1例,2期1例,3期3例。
- 从CPI-613治疗开始至AKI发生时间为51.0(16.0-58.0)天。
- 年龄每增加5岁与AKI风险升高相关(调整HR 2.01,95%CI 1.06-3.79,P=0.03)。
- 4例有随访血清肌酐(AKI后174.8±139.6天),3例肾功能完全恢复,1例部分恢复。
临床怎么用
- 接受CPI-613治疗的患者应监测血清肌酐,警惕AKI发生。
- 高龄患者可能需更密切的肾功能监测。
局限性
- 单中心回顾性设计,样本量小(33例)。
- 部分AKI病例缺乏随访肾功能数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Mitochondrial dysfunction plays an important role in the pathophysiology of kidney disease. Inhibitors of mitochondrial metabolism are being developed for the treatment of solid organ and hematologic malignancies. We describe the incidence and clinical features of acute kidney injury (AKI) in patients treated with the antimitochondrial drug CPI-613. METHODS: We identified 33 patients with relapsed or refractory malignancy, previously enrolled in 3 open-label phase II studies, who received single-agent CPI-613 chemotherapy. AKI was defined by the Kidney Disease Improving Global Outcomes serum creatinine criteria. Participants were followed for a median (25th-75th percentile) of 120.0 (74.0-301.0) days. Risk factors for AKI were assessed by proportional hazards regression using univariate and multivariate analyses. RESULTS: Participants had baseline mean (SD) age of 63.8 (11.6) years and serum creatinine 0.9 (0.3) mg/dl. AKI developed in 9 (27%) patients; chart review failed to identify a potential cause of AKI other than CPI-613 administration in 5 (15%) patients, of whom 1 had AKI stage 1, 1 had AKI stage 2, and 3 experienced AKI stage 3. Time from initiation of CPI-613 treatment to AKI was 51.0 (16.0-58.0) days. Age, per 5-year increase, was associated with higher risk of AKI (adjusted hazard ratio 2.01, 95% confidence interval 1.06-3.79, P = 0.03). Follow-up serum creatinine was available in 4 participants 174.8 (139.6) days after the episode of AKI; 3 patients had complete recovery in kidney function and 1 had partial recovery. CONCLUSION: AKI is a possible complication during treatment with mitochondria-targeted chemotherapy.
引用
- Anderson EM, Zhang J, Russell G, et al. A Single-Center Retrospective Study of Acute Kidney Injury Incidence in Patients With Advanced Malignancies Treated With Antimitochondrial Targeted Drug. Kidney Int Rep. 2018. PMID: 30775628. doi:10.1016/j.ekir.2018.10.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。